首页|宣白承气汤治疗痰热壅肺证重症肺炎的临床价值

宣白承气汤治疗痰热壅肺证重症肺炎的临床价值

扫码查看
目的 探讨宣白承气汤对痰热壅肺证重症肺炎患者症状缓解时间、炎症反应及病情严重程度的影响。方法 采用随机数表法将于成都市温江区涌泉街道社区卫生服务中心接受治疗的89例痰热壅肺证重症肺炎患者(2022年2月-2024年2月)分为对照组(44例)和观察组(45例)。对照组患者进行抗感染、化痰等常规西医治疗,观察组患者在对照组的基础上给予宣白承气汤治疗,两组治疗时间均为14d。比较两组疗效(治疗14d后)、症状缓解时间、病情严重程度(治疗前、治疗14d后)和血清生化指标(治疗前、治疗14d后)。结果 治疗14d后,与对照组相比(65。91%),观察组总有效率(86。67%)较高(P<0。05)。与对照组相比,观察组患者退热时间、气喘缓解时间、咳嗽缓解时间均较短(P<0。05)。与治疗前相比,治疗14d后,观察组、对照组急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)、全身炎症反应综合征(SIRS)、临床肺部感染评分(CPIS)、血清降钙素原(PCT)、白细胞介素-13(IL-13)、血清淀粉样蛋白A(SAA)水平均降低,且观察组均低于对照组(P<0。05)。结论 宣白承气汤治疗痰热壅肺证重症肺炎患者可有效缩短其症状缓解时间,减轻病情严重程度及炎症反应,整体具有较高的临床应用价值。
Clinical value of Xuanbai Chengqi Decoction in treating severe pneumonia with phlegm-heat obstructing lung syndrome
Objective To investigate the effects of Xuanbai Chengqi Decoction on symptom relief time,inflammatory response and severity of severe pneumonia with phlegm-heat obstructing lung syndrome.Methods A total of 89 patients with severe pneumonia with phlegm heat obstructing lung syndrome(from February 2022 to February 2024)were divided into control group(44 cases)and observation group(45 cases)by random number table method in Yongquan Community Health Service Center,Wenjiang District,Chengdu.The control group received conventional Western medicine treatment such as anti-infection and expectoration,while the observation group received Xuanbai Chengqi Decoction on the basis of the control group.The treatment time of both groups was 14 days.The curative effect(14 days after treatment),symptom remission time,severity of disease(before treatment and 14 days after treatment)and serum biochemical indexes(before treatment and 14 days after treatment)were compared between the two groups.Results After 14 days of treatment,the total effective rate of the observation group(86.67%)was higher than that of the control group(65.91%)(P<0.05).Compared with the control group,the time of fever remission,asthma remission and cough remission in observation group were shorter(P<0.05).After 14 days of treatment,compared to before treatment,the levels of acute physiology and Chronic health status score System Ⅱ(APACHEⅡ),systemic inflammatory response syndrome(SIRS),clinical pulmonary infection score(CPIS),serum procalcitonin(PCT),interleukin-13(IL-13)and serum amyloid A(SAA)were all decreased in observation group and control group,the observation group was lower than the control group(P<0.05).Conclusion Xuanbai Chengqi Decoction can effectively shorten the time of symptom relief,reduce the severity of disease and inflammatory reaction in the treatment of severe pneumonia with phlegm heat obstruction,and has high clinical application value.

Xuanbai Chengqi DecoctionSyndrome of phlegm-heat obstructing lungSevere pneumoniaInflammatory response

邓昌龙

展开 >

成都市温江区涌泉街道社区卫生服务中心,四川 成都 611139

宣白承气汤 痰热壅肺证 重症肺炎 炎症反应

2025

首都食品与医药
《首都医药》杂志社

首都食品与医药

影响因子:0.389
ISSN:1005-8257
年,卷(期):2025.32(1)